Year: 2024
Type: dissertation
Abstract: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and accounts for the 5 th most common cancer and the 3 rd leading cause of cancer mortalities worldwide.HCC occurs most commonly in patients with underlying liver diseases such as cirrhosis caused by hepatitis B and C virus infections.Since patients with early-stage HCC do not present overt symptoms, this disease is often detected in very late stages.Curable treatment options are currently very limited and include surgery and liver transplantation, which is why it is of utmost importance to find suitable biomarkers for early detection.Phosphoglucomutase 5 (PGM5) belongs to the α-D-phosphohexomutase (PHM) family comprised of five members in humans and mice.Members of this family play roles in catalyzing essential metabolic reactions with PGM1 representing the most widely expressed and fully characterized in terms of structure and function.In contrast to the other family members, PGM5 is predominantly expressed in muscle tissues and localizes to the adherens junctions of smooth muscle cells (SMCs).Also, in contrast to the other PHM proteins that exhibit enzyme activity, data suggest that PGM5 may play a structural function within cells.This is supported by studies finding interactions between PGM5 and cytoskeletal proteins in a manner that enhances cell-cell adhesion and contractility.For reasons that have not been determined, decreased levels of PGM5 mRNA have been shown to be a common characteristic in various cancers, including HCC.However, little is known regarding the role that PGM5 or its decreased levels play in tumor development and progression.This thesis dissertation presents the results of our investigation of the role that PGM5 may play in HCC progression with the following specific objectives: (i), determine whether PGM5 protein levels change in HCC in both human and mice, (ii) evaluate whether the localization of PGM5 is altered during HCC progression in the liver, and (iii) determine the in vivo effects of PGM5 overexpression and KO on HCC progression using mouse models.The data presented herein show that, in human patient biopsies of HCC and other types of cancer, PGM5 protein levels are decreased.By using a mouse model of HCC, we show that PGM5 protein levels decrease over time as the tumor progresses.In the healthy liver, PGM5 is located in the smooth muscle cells surrounding arteries and veins of healthy blood vessels, most notably at the portal triads of the classic hepatic lobule.When HCC forms and progresses, this organized structure completely changes, causing a decrease in PGM5 protein levels.At late-stage HCC, abnormal masses
Author: Martinez Rodriguez, Verena
Institution: University of Hawaiʻi at Mānoa
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7033194030
